650,000 options granted to Fulcrum Therapeutics (FULC) CEO Alex Sapir

Rhea-AI Filing Summary

Fulcrum Therapeutics, Inc. reported a new equity award to its President and Chief Executive Officer, Alex Sapir. On February 2, 2026, Sapir received a stock option to buy 650,000 shares of Fulcrum common stock at an exercise price of $10.72 per share.

The option is scheduled to vest in equal quarterly installments over four years, beginning on the vesting commencement date of January 1, 2026, and depends on Sapir’s continued service on each vesting date. Following this grant, Sapir beneficially owns 650,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sapir Alex

(Last) (First) (Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option - Right to Buy	$10.72	02/02/2026		A		650,000		(1)	02/01/2036	Common Stock	650,000	$0.00	650,000	D

Explanation of Responses:

1. This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.

Remarks:

President & Chief Executive Officer

	/s/ Greg Tourangeau as attorney-in-fact for Alex Sapir	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Fulcrum Therapeutics (FULC) report for Alex Sapir?

Fulcrum Therapeutics reported a new stock option grant to Alex Sapir. On February 2, 2026, the company awarded its President and CEO an option to purchase 650,000 shares of common stock at an exercise price of $10.72 per share, recorded as a direct holding.

How many stock options did Alex Sapir receive from Fulcrum Therapeutics (FULC)?

Alex Sapir received options covering 650,000 shares of Fulcrum stock. These derivative securities are structured as a stock option right to buy common shares and are shown as 650,000 derivative securities beneficially owned directly following the reported Form 4 transaction on February 2, 2026.

What is the exercise price of Alex Sapir’s Fulcrum Therapeutics (FULC) stock options?

The exercise price of Alex Sapir’s stock options is $10.72 per share. This price applies to the 650,000-share stock option grant reported as a derivative security. The options give Sapir the right to buy Fulcrum common stock at this fixed price if and when they vest.

What is the vesting schedule for Alex Sapir’s Fulcrum Therapeutics (FULC) stock options?

The options vest quarterly over four years starting January 1, 2026. The grant is scheduled to vest in equal quarterly installments, with each portion subject to Sapir’s continued service on the applicable vesting date, aligning long-term incentives with ongoing leadership at the company.

What role does Alex Sapir hold at Fulcrum Therapeutics (FULC) in this Form 4?

Alex Sapir is reported as both a director and an officer. The filing identifies him as President and Chief Executive Officer of Fulcrum Therapeutics, Inc., and the reported 650,000-share stock option grant reflects compensation tied to his executive and board responsibilities.

Is Alex Sapir’s Fulcrum Therapeutics (FULC) option grant held directly or indirectly?

The 650,000-share stock option grant is held directly. The Form 4 lists the ownership form for the derivative securities as “D” for direct, with no nature-of-ownership footnote shifting voting or investment authority to another entity or person.